Tenaya Therapeutics, Inc.
NASDAQ:TNYA
0.6702 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 17.664 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 2.123 | 2.155 | 2.987 | 2.977 | 2.971 | 2.884 | 2.853 | 2.802 | 1.76 | 1.298 | 1.112 | 1.055 | 0.998 | 0.689 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | -2.123 | -2.155 | 14.677 | -2.977 | -2.971 | -2.884 | -2.853 | -2.802 | -1.76 | -1.298 | -1.112 | -1.055 | -0.998 | -0.689 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0.831 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 18.688 | 20.35 | 22.649 | 25.055 | 22.865 | 23.091 | 26.477 | 25.605 | 25.748 | 23.758 | 20.876 | 24.155 | 20.953 | 12.944 | 10.906 | 9.59 | 8.364 | 8.48 | 6.958 | 7.297 |
| General & Administrative Expenses
| 5.964 | 6.361 | 8.174 | 8.707 | 8.581 | 7.829 | 8.627 | 8.118 | 8.802 | 7.54 | 7.743 | 6.999 | 5.211 | 5.356 | 4.331 | 3.515 | 1.958 | 1.972 | 1.914 | 1.969 |
| Selling & Marketing Expenses
| 0 | 0 | -2.123 | -2.155 | -2.987 | -2.977 | -2.971 | -2.884 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.964 | 6.361 | 6.051 | 6.552 | 5.594 | 4.852 | 5.656 | 5.234 | 8.802 | 7.54 | 7.743 | 6.999 | 5.211 | 5.356 | 4.331 | 3.515 | 1.958 | 1.972 | 1.914 | 1.969 |
| Other Expenses
| 0 | 0 | -0.001 | 0.082 | 0.041 | 0.001 | -0.002 | 0.013 | -0.003 | 0.006 | 0 | -0.001 | -0.054 | 0.015 | 0.018 | -0.002 | -0.001 | 0.15 | 0.123 | 0.158 |
| Operating Expenses
| 24.652 | 26.711 | 28.7 | 31.607 | 28.459 | 27.943 | 32.133 | 30.839 | 34.55 | 31.298 | 28.619 | 31.154 | 26.164 | 18.3 | 15.237 | 13.105 | 10.322 | 10.452 | 8.872 | 9.266 |
| Operating Income
| -24.652 | -26.711 | -30.823 | -33.762 | -31.446 | -30.92 | -35.104 | -33.723 | -34.55 | -31.298 | -28.619 | -31.154 | -26.164 | -18.3 | -15.237 | -13.105 | -10.322 | -10.452 | -8.872 | -9.266 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -1.78 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.816 | 1.077 | 1.392 | 1.534 | 1.511 | 1.777 | 1.835 | 1.986 | 1.034 | 0.602 | 0.222 | 0.098 | 0.013 | 0.038 | 0.027 | 0.007 | 0.004 | 0.157 | 0.141 | 0.215 |
| Income Before Tax
| -23.836 | -25.634 | -29.431 | -32.228 | -29.935 | -29.143 | -33.269 | -31.737 | -33.516 | -30.696 | -28.397 | -31.056 | -26.151 | -18.262 | -15.21 | -13.098 | -10.318 | -10.295 | -8.731 | -9.051 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -1.695 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 2.112 | 2.943 | 3.017 | 2.849 | 2.842 | 0.92 | -0.602 | -0.222 | -0.098 | -26.138 | -0.038 | -0.036 | -0.007 | -0.009 | -0.157 | -0.159 | -0.215 |
| Net Income
| -23.836 | -25.634 | -29.431 | -32.228 | -29.935 | -29.143 | -33.269 | -31.737 | -34.436 | -30.094 | -28.175 | -30.958 | -26.151 | -18.262 | -15.21 | -13.098 | -10.318 | -10.295 | -8.731 | -9.051 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -1.695 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.28 | -0.3 | -0.34 | -0.4 | -0.44 | -0.39 | -0.45 | -0.43 | -0.62 | -0.73 | -0.68 | -0.75 | -0.63 | -0.68 | -0.41 | -0.48 | -0.38 | -0.38 | -0.32 | -0.33 |
| EPS Diluted
| -0.28 | -0.3 | -0.34 | -0.4 | -0.44 | -0.39 | -0.45 | -0.43 | -0.62 | -0.73 | -0.68 | -0.75 | -0.63 | -0.68 | -0.41 | -0.48 | -0.38 | -0.38 | -0.32 | -0.33 |
| EBITDA
| -22.563 | -24.61 | -28.7 | -31.607 | -29.265 | -28.739 | -32.909 | -31.593 | -32.433 | -29.211 | -27.322 | -30.188 | -25.039 | -17.554 | -14.502 | -12.416 | -9.664 | -9.821 | -8.262 | -8.682 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -1.611 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |